Abnormalities, Multiple Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Abnormalities, Multiple. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Abnormalities, Multiple receives a directional score of 59/100, combining unmet need (63/100), competitive intensity (96/100) and market attractiveness (95/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

Congenital abnormalities that affect more than one organ or body structure.

The reproducible record is Patsnap disease ID c0aeccf13e244395bab8cf7abafc131a and MeSH identifier D000015. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: Heart Disease and Stroke Statistics—2022 Update Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association

• The GBD 2020 study produces comprehensive and comparable estimates of disease burden for 370 reported causes and 88 risk factors for 204 coun­ tries and territories from 1990 to 2020. (Data cour­ tesy of the Global Burden of Disease Study 2020.) In 2020: — The prevalence of congenital heart anomalies was 14.78 million (95% UI, 13.35–16.47 mil­ lion) cases. — There were 0.21 million (95% UI, 0.18–0.25 mil­ lion) deaths estimated for congenital heart anom­ alies worldwide. — Age-standardized mortality rates of congenital heart anomalies were highest in Oceania, North Africa and the Middle East, and the Caribbean. They were lowest in high-income Asia Pacific, Western Europe, and Australasia (Chart 17-6). — The age-standardized prevalence of congenital heart anomalies was highest in high-income Asia Pacific, Central Asia, and Western Europe (Chart 17-7). • In a 2019 systematic review including 103 632 049 live births globally, the mean prevalence of CCDs globally was 8.224 per 1000. Prevalence of CCDs in Africa was estimated at ≈25% of that in other regions, likely attributable to sparse population-level data and low diagnostic access.118 • According to a systematic review and meta-analysis of CCD data from China, birth prevalence of CCD has increased from 0.2 per 1000 live births (1980– 1984) to 4.9 per 1000 live births (2015–2019), with higher rates among males (4.2 per 1000 ver­ sus 3.5 per 1000), individuals living in urban com­ pared with rural areas (2.5 per 1000 versus 4.3 per 1000), and those in higher income brackets (no data from lower-income regions but 4.0 per 100

Review source

Epidemiology evidence 2: China CDC Weekly Reports (Vol. 7 No. 52 Dec. 26, 2025) Burden and Risk Factors of Gout, Low Back Pain, Osteoarthritis,and Rheumatoid Arthritis — China, 1990–2023

Data were obtained from the GBD 2023 dataset, covering 375 diseases and 88 risk factors in 204 countries and territories. We extracted incidence, prevalence, DALYs, and age-standardized rates (ASRs) gor gout, LBP, OA, and RA in China from the global health data exchange (GHDx) platform. This study followed Guidelines for accurate and transparent health estimates reporting (GATHER) and required no ethical approval, as no personal or sensitive data was used (3). Disease burden was assessed via incidence, prevalence, and DALYs (measuring life loss/disability). We used Joinpoint regression (version 5.0.2, National Cancer Institute, Bethesda, United States) to identify significant trend changes, calculating the Annual Percentage Change (APC). Time patterns were quantified using the Estimated Annual Percentage Change (EAPC), with trend direction determined by its 95% confidence interval (CI). We analyzed disease distribution by gender and 17 age groups and assessed risk factors contributing to DALYs. Future burden was predicted using the Autoregressive Integrated Moving Average (ARIMA) model, selected for its high accuracy and widely utilized in relevant epidemiological research (4).

Review source

Epidemiology evidence 3: Epidemiology of Sjögren’s: A Systematic Literature Review Epidemiology of Sjo¨gren’s: A Systematic LiteratureReview

100,000 persons [21–23, 26]. The range of inci- dence estimates identified in this SLR exceeded the range found in Qin et al. 2015 (6.9–20.1 per 100,000 person-years) [11], with the prevalence estimates identified in both studies proving to be even more variable. The current SLR identi- fied a prevalence range of 12.4–13.1 per 100,000 person-years or 22.0–770.0 per 100,000 persons (once metrics were scaled to 100,000 persons) [27, 34]. Qin et al. 2015 observed even larger variability in prevalence estimates, ranging from 11.3–3790.1 per 100,000 persons [11]. This wide variation affirms the need for robust, population-wide epidemiology studies to fur- ther understand the incidence and prevalence of Sjo¨gren’s.

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Abnormalities, Multiple, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Abnormalities, Multiple thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: COL1A1

Type I collagen is a member of group I collagen (fibrillar forming collagen).

The mechanism anchor is COL1A1, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 3465 registered studies.

• NCT07785011 — Effect of Sensory Integration on Gross and Balance on Children With Down Syndrome; Recruiting; Not Applicable; sponsor Cairo University; enrollment 40.
• NCT07782827 — CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS); Not yet recruiting; Phase 3; sponsor Ionis Pharmaceuticals, Inc.; enrollment 30.
• NCT07781943 — The Effect of Diaphragmatic Breathing Exercises Before Gastroscopy on Anxiety, Fear, and Vital Signs; Recruiting; Not Applicable; sponsor Eastern Mediterranean University; enrollment 64.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

The query returned 5 directly matched 2023–2026 transactions.

• Foundation for Angelman Syndrome Therapeutics Announces Agreement with Apertura Gene Therapy for Access to Blood-Brain Barrier-Crossing Capsid (2026-08-05). Review stage, rights, territory, milestones and economics before using it as a comparable.
• AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease (2024-05-13). Review stage, rights, territory, milestones and economics before using it as a comparable.
• Spexis announces that Santhera Pharmaceuticals has terminated the February 2018 agreement wherein Spexis (formerly Polyphor) out-licensed worldwide rights of lonodelestat (2024-04-17). Review stage, rights, territory, milestones and economics before using it as a comparable.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate COL1A1 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Abnormalities, Multiple merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Abnormalities, Multiple is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.